title: Reforming the cancer drug fund.
authors.affiliation: Brunel University London, London, UK.
authors.forename: Martin
authors.initials: M
authors.lastname: Buxton
authors.affiliation: Brunel University London, London, UK.
authors.forename: Louise
authors.initials: L
authors.lastname: Longworth
authors.affiliation: University of Southampton, Southampton, UK j.p.raftery@soton.ac.uk.
authors.forename: James
authors.initials: J
authors.lastname: Raftery
authors.affiliation: Centre for Health Economics, University of York, York, UK.
authors.forename: Mark
authors.initials: M
authors.lastname: Sculpher
authors.affiliation: Office of Health Economics, London, UK.
authors.forename: Adrian
authors.initials: A
authors.lastname: Towse
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D003362:Cost-Benefit Analysis; D005376:Financial Management / Q000191:economics*; D005102:Health Expenditures; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D013222:State Medicine / Q000191:economics*; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents